Contact Us
Drug Search Results
More Filters [+]

QLC-1101

Alternative Names: QLC-1101, QLC 1101, QLC1101
Latest Update: 2024-05-08
Latest Update Note: Clinical Trial Update

Product Description

QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors. (Sourced from: https://clinicaltrials.gov/study/NCT06403735)

Mechanisms of Action: KRAS G12D Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Qilu
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for QLC-1101

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Colorectal Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
QLC1101-101

P1

Recruiting

Pancreatic Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer

2026-05-31

34%

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions